Published in Hepatology on November 01, 2002
GS-7977 With Ribavirin for Hepatitis C (SPARE) | NCT01441180
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV | NCT01443923
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82
Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis (2012) 2.19
RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci U S A (2003) 1.84
Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus-mediated liver disease posttransplantation. Hepatology (2012) 1.82
The epidemiology of hepatitis C infection in the United States. J Gastroenterol (2007) 1.71
Use of the AST to platelet ratio index in HCV/HIV co-infected patients. Aliment Pharmacol Ther (2011) 1.57
Concern Prevalence of hepatitis B and hepatitis C infection in Libya: results from a national population based survey. BMC Infect Dis (2014) 1.37
Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health (2012) 1.35
Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg (2003) 1.35
Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation. J Biol Chem (2011) 1.32
Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf (2013) 1.31
Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis (2008) 1.26
Structure-function relationships of the viral RNA-dependent RNA polymerase: fidelity, replication speed, and initiation mechanism determined by a residue in the ribose-binding pocket. J Biol Chem (2007) 1.23
Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage. Can J Gastroenterol (2007) 1.21
Current and future disease progression of the chronic HCV population in the United States. PLoS One (2013) 1.17
Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect. J Virol (2006) 1.16
Neurocognitive effects of HIV, hepatitis C, and substance use history. J Int Neuropsychol Soc (2011) 1.15
Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology (2010) 1.13
The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis (2012) 1.10
Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther (2013) 1.09
Long-range interaction networks in the function and fidelity of poliovirus RNA-dependent RNA polymerase studied by nuclear magnetic resonance. Biochemistry (2010) 1.08
Clinicopathologic correlates of hepatitis C virus in brain: a pilot study. J Neurovirol (2008) 1.08
A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. Virol J (2005) 1.06
Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. J Med Virol (2009) 1.05
Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Dig Dis Sci (2008) 1.04
Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009-2010. Am J Public Health (2012) 1.04
Prisons as social determinants of hepatitis C virus and tuberculosis infections. Public Health Rep (2010) 1.02
Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. J Clin Gastroenterol (2009) 1.01
A novel duplex real-time reverse transcriptase-polymerase chain reaction assay for the detection of hepatitis C viral RNA with armored RNA as internal control. Virol J (2010) 1.00
Hepatitis C virus infection and kidney disease: a meta-analysis. Clin J Am Soc Nephrol (2012) 0.98
Safety of interferon beta treatment for chronic HCV hepatitis. World J Gastroenterol (2004) 0.98
Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig Dis Sci (2011) 0.97
Hepatitis C Virus infections trends in Italy, 1996-2006. Hepat Mon (2011) 0.97
Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol (2009) 0.96
Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol (N Y) (2011) 0.96
Involvement of a bovine viral diarrhea virus NS5B locus in virion assembly. J Virol (2004) 0.95
Alcohol-related and viral hepatitis C-related cirrhosis mortality among Hispanic subgroups in the United States, 2000-2004. Alcohol Clin Exp Res (2010) 0.95
Sociodemographic trends in national ambulatory care visits for hepatitis C virus infection. Dig Dis Sci (2009) 0.95
A systematic review of provider knowledge of hepatitis C: is it enough for a complex disease? Dig Dis Sci (2007) 0.93
Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy. Am J Public Health (2012) 0.93
Predicting the probable outcome of treatment in HCV patients. Therap Adv Gastroenterol (2009) 0.92
New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis (2016) 0.91
Risk factors associated with Hepatitis C among female substance users enrolled in community-based HIV prevention studies. BMC Res Notes (2011) 0.90
Automated liver elasticity calculation for MR elastography. J Magn Reson Imaging (2015) 0.90
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol (2011) 0.90
Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Protein Cell (2010) 0.90
INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob Agents Chemother (2011) 0.89
Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. Virology (2008) 0.89
Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol (2012) 0.88
Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy. N Am J Med Sci (Boston) (2014) 0.88
Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues. Dig Dis Sci (2012) 0.87
Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus. J Clin Microbiol (2007) 0.87
Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. Immunology (2007) 0.87
Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking. Hepatology (2011) 0.87
Demographics, socio-behavioral factors, and drug use patterns: what matters in spontaneous HCV clearance? J Med Virol (2012) 0.85
Vertical hepatitis C virus transmission: Main questions and answers. World J Hepatol (2014) 0.85
Hepatitis-C prevalence in an urban native-American clinic: a prospective screening study. J Natl Med Assoc (2007) 0.84
Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population. BMC Gastroenterol (2013) 0.84
Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation (2011) 0.84
Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication. World J Gastroenterol (2014) 0.84
Reliability and validity of a self-efficacy instrument for hepatitis C antiviral treatment regimens. J Viral Hepat (2011) 0.83
SH2 modified STAT1 induces HLA-I expression and improves IFN-γ signaling in IFN-α resistant HCV replicon cells. PLoS One (2010) 0.83
A Rapid Bedside Screen to Predict Unplanned Hospitalization and Death in Outpatients With Cirrhosis: A Prospective Evaluation of the Clinical Frailty Scale. Am J Gastroenterol (2016) 0.83
Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women? World J Hepatol (2016) 0.83
Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples. Virol J (2013) 0.83
Vaccine-derived mutation in motif D of poliovirus RNA-dependent RNA polymerase lowers nucleotide incorporation fidelity. J Biol Chem (2013) 0.82
The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci (2011) 0.82
Complete blood count, measures of iron status and inflammatory markers in inner-city African Americans with undiagnosed hepatitis C seropositivity. Clin Chim Acta (2010) 0.82
Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009. PLoS One (2015) 0.82
ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. J Med Virol (2012) 0.81
Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. J Psychosom Res (2011) 0.80
Effects of liver disease on the well-being of persons living with HIV. J Assoc Nurses AIDS Care (2008) 0.79
Effects of paracentesis on hemodynamic parameters and respiratory function in critically ill patients. BMC Gastroenterol (2014) 0.79
In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother (2013) 0.79
A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System. J Urban Health (2015) 0.78
Prevalence and knowledge of hepatitis C in a middle-aged population, Dunedin, New Zealand. World J Gastroenterol (2015) 0.78
Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. Clinicoecon Outcomes Res (2010) 0.77
Validation of the MOS-HIV as a measure of health-related quality of life in persons living with HIV and liver disease. AIDS Care (2010) 0.77
Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective. Endocr Pract (2013) 0.77
Age cohort differences in illicit drug use and hepatitis C among African American substance users. J Addict Dis (2014) 0.77
Nucleobase but not Sugar Fidelity is Maintained in the Sabin I RNA-Dependent RNA Polymerase. Viruses (2015) 0.76
HCV in liver transplantation. Semin Immunopathol (2012) 0.76
Novel drugs in the management of difficult-to-treat hepatitis C genotypes. Hepat Med (2013) 0.76
Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama. Clin Infect Dis (2015) 0.76
Faldaprevir for the treatment of hepatitis C. Int J Mol Sci (2015) 0.76
Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure. Dig Dis Sci (2007) 0.75
Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection. Clin Mol Hepatol (2014) 0.75
Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol (2015) 0.75
Patients with chronic hepatitis C undergoing watchful waiting: Exploring trajectories of illness uncertainty and fatigue. Res Nurs Health (2010) 0.75
Saponin inhibits hepatitis C virus propagation by up-regulating suppressor of cytokine signaling 2. PLoS One (2012) 0.75
Predictive role of acute phase reactants in the response to therapy in patients with chronic hepatitis C virus infection. Gut Liver (2012) 0.75
Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients. AIDS Behav (2016) 0.75
Direct-acting antiviral agents in patients with hepatitis C cirrhosis. Gastroenterol Hepatol (N Y) (2012) 0.75
Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients. Can J Gastroenterol Hepatol (2016) 0.75
Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat (2011) 0.75
Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy. Case Rep Pulmonol (2015) 0.75
An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep (2017) 0.75
Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: A case report. World J Hepatol (2010) 0.75
The role of obstetrician/gynecologists in the management of hepatitis C virus infection. Infect Dis Obstet Gynecol (2008) 0.75
Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment. World J Hepatol (2016) 0.75